Journals that publish Pfizer funded research most often
| # | Journal | Articles naming it | Indexing | Impact factor* | Median review time |
|---|---|---|---|---|---|
| 1 | Infectious Diseases and Therapy | 26 of 200 | SCIE | 5.35 | 64 days |
| 2 | Cardiology and Therapy | 14 of 97 | ESCI | 4.04 | 70 days |
| 3 | Targeted Oncology | 12 of 157 | SCIE | 4.89 | 100 days |
| 4 | Dermatology and Therapy | 11 of 200 | SCIE | 4.01 | 62 days |
| 5 | Rheumatology and Therapy | 9 of 165 | SCIE | 3.53 | 71 days |
| 6 | Revista Iberoamericana de Micología | 8 of 41 | SCIE | 1.76 | n/a |
| 7 | The Breast | 8 of 200 | SCIE | 2.32 | n/a |
| 8 | Clinical Pharmacokinetics | 7 of 200 | SCIE | 5.04 | 145 days |
| 9 | Future Oncology | 7 of 200 | SCIE | 2.95 | 122 days |
| 10 | Advances in Therapy | 6 of 200 | SCIE | 4.26 | 74 days |
| 11 | Pulmonary Therapy | 6 of 118 | ESCI | 3.02 | 54 days |
| 12 | American Journal of Clinical Dermatology | 5 of 178 | SCIE | 9.72 | 129 days |
| 13 | Amyloid | 5 of 138 | SCIE | 3.63 | 103 days |
| 14 | Crohn s & Colitis 360 | 5 of 153 | ESCI | 2.29 | n/a |
| 15 | Inflammatory Bowel Diseases | 5 of 200 | SCIE | 2.75 | n/a |
| 16 | Organic Process Research & Development | 5 of 200 | SCIE | 3.66 | n/a |
| 17 | Patient | 5 of 129 | SCIE SSCI | 3.56 | 124 days |
| 18 | Therapeutic Advances in Musculoskeletal Disease | 5 of 153 | SCIE | 3.60 | n/a |
| 19 | Anaerobe | 4 of 173 | SCIE | 3.69 | n/a |
| 20 | BMJ Open Gastroenterology | 4 of 176 | ESCI | 4.03 | n/a |
| 21 | Clinical Microbiology and Infection | 4 of 200 | SCIE | 4.70 | n/a |
| 22 | Heart Failure Clinics | 4 of 151 | SCIE | 1.08 | n/a |
| 23 | Infectious Disease Clinics of North America | 4 of 165 | SCIE | 3.36 | n/a |
| 24 | Influenza and Other Respiratory Viruses | 4 of 200 | SCIE | 4.02 | 142 days |
| 25 | International Journal of Antimicrobial Agents | 4 of 200 | SCIE | 4.21 | n/a |
| 26 | Lara D. Veeken | 4 of 200 | SCIE | 2.47 | n/a |
| 27 | Neurology and Therapy | 4 of 200 | SCIE | 4.09 | 68 days |
| 28 | Pain and Therapy | 4 of 200 | SCIE | 6.63 | 57 days |
| 29 | PharmacoEconomics - Open | 4 of 159 | ESCI | 2.97 | 179 days |
| 30 | British Journal of Haematology | 3 of 200 | SCIE | 2.77 | 99 days |
| 31 | Clinical & Translational Oncology | 3 of 200 | SCIE | 2.72 | 76 days |
| 32 | Dermatologic Clinics | 3 of 166 | SCIE | 2.44 | n/a |
| 33 | eJHaem | 3 of 200 | ESCI | 1.34 | 83 days |
| 34 | Expert Opinion on Biological Therapy | 3 of 200 | SCIE | 3.41 | 72 days |
| 35 | IJID Regions | 3 of 200 | ESCI | 2.22 | n/a |
| 36 | Immunology and Allergy Clinics of North America | 3 of 183 | SCIE | 1.80 | n/a |
| 37 | Infectious Diseases Now | 3 of 200 | SCIE | 2.36 | n/a |
| 38 | JAC-Antimicrobial Resistance | 3 of 200 | ESCI | 2.58 | n/a |
| 39 | Joint Bone Spine | 3 of 200 | SCIE | 2.59 | n/a |
| 40 | Medical Mycology Case Reports | 3 of 162 | ESCI | 1.16 | n/a |
| 41 | Mycoses | 3 of 200 | SCIE | 4.06 | 94 days |
| 42 | Rheumatology Advances in Practice | 3 of 200 | ESCI | 1.30 | n/a |
| 43 | The Journal of Clinical Pharmacology | 3 of 200 | SCIE | 2.04 | 87 days |
| 44 | Therapeutic Advances in Endocrinology and Metabolism | 3 of 145 | SCIE | 5.58 | n/a |
| 45 | Bioanalysis | 2 of 200 | SCIE | 2.71 | 107 days |
| 46 | Clinical and Translational Science | 2 of 200 | SCIE | 5.10 | 120 days |
| 47 | Endocrine and Metabolic Science | 2 of 124 | Scopus | 2.84 | n/a |
| 48 | Haemophilia | 2 of 200 | SCIE | 2.23 | 123 days |
| 49 | Headache The Journal of Head and Face Pain | 2 of 200 | SCIE | 3.50 | 128 days |
| 50 | npj Primary Care Respiratory Medicine | 2 of 180 | SCIE | 2.92 | 128 days |
"Articles naming" counts the research articles (of up to 200 from the last 24 months) whose funder list names Pfizer. *Impact factor calculated from OpenAlex open data, not the official Clarivate value. Review time: median days from submission to acceptance, from the dates publishers deposit in Crossref.
Funders named alongside Pfizer
Other funders that appear in the same journals. Their pages show where their funded research is published.
Find a journal for your paper
A journal that often publishes Pfizer funded work is a good start, but the fit with your topic matters most. The free Journal Finder matches your title or abstract to the journals that published the closest papers.
Open the Journal Finder →Check your APC waiverIs my paper ready to submit?
Frequently asked questions
Which journals publish the most Pfizer funded research?
In the recent research articles we checked, the journals that name Pfizer as a funder most often are Infectious Diseases and Therapy, Cardiology and Therapy, Targeted Oncology, Dermatology and Therapy, Rheumatology and Therapy. In all, 64 journals name it.
Does publishing in these journals help my Pfizer grant?
These journals already publish work supported by Pfizer, so editors and reviewers know this kind of research. Whether a journal suits your paper still depends on its scope, indexing and review time, shown for each journal in the table.
Does Pfizer pay the article processing charge (APC)?
Many funders pay or reimburse open access fees under their open access policy, but the rules differ by funder and by grant. Check Pfizer's open access policy and your grant terms; for country-based waivers, use the free APC waiver checker.
Where does this data come from?
From the funder information publishers deposit with each article in Crossref. For each journal, ScholarsColab looked at up to 200 research articles from the last 24 months and counted the funders they name. Not every publisher deposits funders, so a journal can be missing.
